Entera Bio

Entera Bio Revenue

The The revenue of Entera Bio (ENTX) as of Nov 22, 2026 is 42,000.00 USD. In the previous year, The revenue was 181,000.00 USD — a change of -76.80% (lower).

Revenue

42,000.00USD

YoY

-76.80%

Last updated:

In 2025, Entera Bio's sales reached 42,000.00 USD, a -76.80% difference from the 181,000.00 USD sales recorded in the previous year.

Revenue at Entera Bio has contracted by 29.8% per year over the past 7 years to 42,000.00 USD.

The Entera Bio Revenue history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
Date
Revenue
Jan 1, 2020
365,000.00 USD
Jan 1, 2021
571,000.00 USD
Jan 1, 2022
134,000.00 USD
Jan 1, 2023
14,000.00 USD
Jan 1, 2024
181,000.00 USD
Jan 1, 2025
42,000.00 USD
Jan 1, 2026 (e)
0.00 USD
Jan 1, 2027 (e)
0.00 USD
The Entera Bio Revenue history
YEARRevenueYoY
est0.00USD—
est0.00USD-100.00%
42,000.00USD-76.80%
181,000.00USD+1,192.86%
14,000.00USD-89.55%
134,000.00USD-76.53%
571,000.00USD+56.44%
365,000.00USD+54.66%
236,000.00USD-52.80%
500,000.00USD—
0.00USD—
0.00USD—
0.00USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Entera Bio Revenue

Entera Bio Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2020
365,000.00 USD
-11.13 M USD
-9.98 M USD
Jan 1, 2021
571,000.00 USD
-12.22 M USD
-12.19 M USD
Jan 1, 2022
134,000.00 USD
-13.02 M USD
-13.07 M USD
Jan 1, 2023
14,000.00 USD
-8.94 M USD
-8.89 M USD
Jan 1, 2024
181,000.00 USD
-9.59 M USD
-9.54 M USD
Jan 1, 2025
42,000.00 USD
-11.53 M USD
-11.44 M USD
Jan 1, 2026 (e)
0.00 USD
-34.68 M USD
-12.42 M USD
Jan 1, 2027 (e)
0.00 USD
0.00 USD
-16.19 M USD

Entera Bio Margins

Entera Bio stock margins

The Entera Bio margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Entera Bio. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Entera Bio.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2020
42.74 %
-3,050.14 %
-2,735.07 %
Jan 1, 2021
34.68 %
-2,139.58 %
-2,134.33 %
Jan 1, 2022
24.63 %
-9,714.18 %
-9,754.48 %
Jan 1, 2023
-400.00 %
-63,857.14 %
-63,492.85 %
Jan 1, 2024
4.97 %
-5,295.58 %
-5,271.27 %
Jan 1, 2025
-71.43 %
-27,450.00 %
-27,235.72 %
Jan 1, 2026 (e)
-71.43 %
- %
- %
Jan 1, 2027 (e)
-71.43 %
0.00 %
- %

Entera Bio Stock analysis

What does Entera Bio do? Entera Bio Ltd is an emerging biotechnology company focused on developing oral medications to treat unmet medical needs. The company was founded in 2010 and is headquartered in Jerusalem, Israel. Its history began with the discovery of the "EnteraGam" molecule in the intestinal cells of breastfed infants, which helps them fight infections. This led to the development of EnteraGam for the treatment of various autoimmune diseases. The company's business model is based on developing oral formulations for existing drugs and discovering and developing new molecules. Its focus areas are osteoporosis, hypoparathyroidism, chronic kidney disease, and autoimmune diseases. Entera Bio is divided into three business divisions: the Oral Protein Delivery Platform, the Oral Parathyroid Hormone (PTH) Platform, and the Collagen-based Platform for Wound Healing. Its products include EB611, a candidate for hypoparathyroidism treatment, EB613 for osteoporosis treatment, and EB612 for chronic kidney disease. These products have potential to improve the lives of millions of patients worldwide. Entera Bio is one of the most popular companies on Eulerpool.

Revenue Details

Understanding Entera Bio's Sales Figures

The sales figures of Entera Bio originate from the total revenue accrued from goods sold or services provided during a specific time period. These numbers are a direct reflection of the company’s ability to translate its products or services into revenue, indicating the demand and market presence.

Year-to-Year Comparison

Analyzing Entera Bio’s yearly sales data offers insights into the company’s growth and stability. An increase in sales suggests a growing demand for its offerings, efficient marketing, or expansion into new markets. Conversely, a decline might indicate market saturation, increased competition, or less effective strategies.

Impact on Investments

Investors often scrutinize Entera Bio's sales data to evaluate its financial health and growth prospects. Consistent sales growth can be a promising indicator of the company’s profitability and potential return on investment, influencing stock prices and investor confidence.

Interpreting Sales Fluctuations

Increases in Entera Bio’s sales indicate market growth, innovation, or effective marketing, often leading to a surge in stock prices. A decline, however, can signal challenges requiring strategic adjustments to enhance market share and profitability.

Frequently Asked Questions about Entera Bio stock

The revenue of Entera Bio is 42,000.00 USD in 2025.

The revenue of Entera Bio changed from 181,000.00 USD to 42,000.00 USD, representing a -76.80% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of The revenue Entera Bio since 2006 – with annual values, charts, and detailed analysis.

Revenue is the total value of all goods sold in a period. It is calculated by multiplying the quantity of each product sold by its selling price. Revenue does not include any costs (material costs, personnel costs, etc.), whereas net proceeds only deduct revenue reductions associated with the sale (discounts, etc.).

The revenue's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The revenue's Entera Bio historically and in real time.

The revenue in assessing a stock

Revenue is an important financial measure used in the valuation of stocks. It is a measure of a company's economic activity and can serve as an indicator of the company's success. Revenue is considered one of the most important factors in stock valuation. In addition, revenue can also be used to calculate other financial measures such as earnings per share and price-earnings ratio.

History and utilization of revenue

Revenue has long been considered one of the most important financial indicators. It was used in the 19th century as one of the first financial indicators to measure a company's economic activity. Since then, revenue has been regularly used to evaluate companies.

Revenue is usually calculated as a percentage of the company's equity. It can also be used to determine the overall profitability of a company. There are many different types of revenue that can be used to measure a company's economic activity, such as gross revenue, net revenue, and revenue from international business.

The revenue can also be used to evaluate stocks. For example, the revenue of a company can be used to evaluate the success of the company. If a company has high revenue, it means that it is a profitable company because it has high demand for its products or services.

Calculation and Application of Revenue

In order to calculate a company's revenue, the company's income must be deducted from its expenses. The income can come from various sources, such as sales, licensing fees, services, etc. The expenses can include costs for production, procurement, inventory, sales, and administration.

The revenue can then be used to calculate various financial ratios. For example, the revenue can be used to calculate the price-earnings ratio (P/E ratio) of a company. This is a measure of a company's profitability, calculated by taking the ratio of the stock price to earnings per share.

Revenue can also be used to calculate earnings per share (EPS) of a company. This is a measure of a company's profit per share. EPS is calculated by dividing earnings by the number of shares issued.

Use of revenue by investors

Investors use revenue to evaluate stocks, as revenue is an indicator of a company's success. For example, an investor can compare a company's revenue to see how successful it is. An investor can also use a company's revenue to calculate its price-to-earnings ratio and earnings per share.

An example: An investor looks at a company that has a revenue of 25 million euros. He compares this revenue to that of the competitor, which has a revenue of 35 million euros. The investor can then see that the company with 25 million euros in revenue is less successful than the company with 35 million euros in revenue.

Advantages and Disadvantages of Revenue.

Revenue is a very useful tool for valuing stocks as it measures a company's economic activity. Revenue can also be used to calculate other financial ratios such as the price-earnings ratio and earnings per share.

However, one disadvantage is that revenue alone is not a meaningful indicator of a company's success. It is important to consider revenue in comparison to other financial metrics such as earnings per share and price-to-earnings ratio to get a complete picture of the company.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Entera Bio

All Key Metrics — Entera Bio